NYU Langone Health's Innovative Approach to Cancer Treatment
NYU Langone Health's Perlmutter Cancer Center is set to launch a transformative molecular profiling protocol. This initiative is designed for patients diagnosed with both early-stage and advanced cancers, aiming to better monitor disease progression and connect patients with the most effective therapies currently available.
Enhancing Patient Care with Genomic Diagnostics
The center's research focuses on advancing genomic diagnostics to optimize patient outcomes. This effort will directly inform future clinical practices and accelerate the development of groundbreaking assays and algorithmic diagnostics. A key component of this research is an observational study titled "Serial Molecular Profiling and Monitoring of Human Cancer," which will involve sequencing patients throughout their treatment journeys to gather critical longitudinal data.
Expanding Molecular Testing Accessibility
Regular molecular testing is set to become available for all patients receiving treatment at the Perlmutter Cancer Center's Manhattan facility. This initiative is currently focused on breast, lung, genitourinary, and gastrointestinal cancers. Over time, the goal is to widen this access, ensuring that patients diagnosed with any form of cancer, no matter where they are treated, can benefit from these advancements.
Leadership Driving Transformation in Oncology
Dr. Shridar Ganesan, MD, PhD, and Dr. Kwok-Kin Wong, MD, PhD, are leading this groundbreaking initiative. Dr. Ganesan, esteemed for his expertise in precision oncology, serves as the Center's director, while Dr. Wong, recognized for his pioneering contributions to cancer biology, is the director of scientific innovation. Both leaders emphasize the importance of advancing cancer treatment through innovative research and collaboration.
Significance of Clinical Research
Dr. Ganesan highlighted the importance of this clinical research initiative, referring to it as a significant milestone for the Center. By integrating advanced molecular diagnostics with a multidisciplinary approach, the aim is to tailor treatments that align with each patient’s unique cancer characteristics, ultimately improving treatment outcomes and minimizing toxicity.
Cancer Insights to Drive Patient Benefits
Dr. Wong reiterated the center's commitment to transforming genomic insights into actionable treatment strategies. This collaboration is crucial for redefining cancer care standards and ensuring that patients receive the most effective and targeted treatments.
A Strategic Partnership with Tempus
The research effort is bolstered by a collaborative partnership with Tempus, a technology company focused on advancing precision medicine through innovative diagnostics and the use of artificial intelligence in healthcare. This collaboration will encompass multiple subsequent studies aimed at assay validation, biomarker discovery, and the development of AI-driven predictive models.
Leading the Charge in Cancer Care
The strides made by the Center for Molecular Oncology further establish Perlmutter Cancer Center as a leader in cancer research and treatment. As a National Cancer Institute-designated Comprehensive Cancer Center, it remains dedicated to pushing the boundaries of precision oncology and delivering cutting-edge solutions that enhance cancer patients' outcomes globally.
About NYU Langone Health
NYU Langone Health is a fully integrated health system focused on delivering high-quality patient care. Recognized nationwide for exceptional outcomes, NYU Langone has been ranked No. 1 out of 118 comprehensive academic medical centers for four consecutive years. Offering a comprehensive range of medical services across multiple locations, including the renowned Perlmutter Cancer Center, it strives for excellence in every facet of healthcare delivery.
Contact Information
For more information, please contact Ryan Dziuba at 212-404-4131.
Frequently Asked Questions
What is the purpose of the new molecular profiling protocols?
The protocols aim to monitor cancer treatment effectiveness and patient outcomes by utilizing genomic diagnostics.
Who are the leaders of this initiative?
This initiative is led by Dr. Shridar Ganesan and Dr. Kwok-Kin Wong, both esteemed specialists in oncology.
What patients will benefit from this research?
Initially, patients with breast, lung, genitourinary, and gastrointestinal cancers will be enrolled, with plans to expand to all cancer types.
How will this research impact cancer treatment standards?
This research aims to redefine treatment standards by providing tailored therapies based on individual molecular profiles.
Who is Tempus and what role do they play in this research?
Tempus is a technology company that collaborates with NYU Langone Health to enhance precision medicine through innovative diagnostics and AI applications in healthcare.
